<!DOCTYPE html>
<html lang="en">

  <head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>RareGen</title>
    <link rel="stylesheet" href="/css/styles.css">
    <link
      href="https://fonts.googleapis.com/css2?family=Roboto+Condensed:ital,wght@0,300;0,400;0,700;1,300;1,400;1,700&family=Roboto+Flex:wght@100;200;300;400;500;600;700;800;900;1000&family=Roboto+Mono:ital,wght@0,100;0,200;0,300;0,400;0,500;0,600;0,700;1,100;1,200;1,300;1,400;1,500;1,600;1,700&family=Roboto:ital,wght@0,100;0,300;0,400;0,500;0,700;0,900;1,100;1,300;1,400;1,500;1,700;1,900&display=swap"
      rel="stylesheet" />
  </head>

  <body>
    <!-- BACKGROUND -->
    <div class="background"></div>
    <!-- HEADER -->
    <header>
      <a href="/index.html">
        <h1 class="logo">RareGen</h1>
      </a>
      <div class="site-management">
        <button class="user-entrance" id="signup" onmousedown="changeBackgroundColor(this, '#666666')"
          onmouseup="revertBackgroundColor(this)" onmouseenter="changeBackgroundColor(this, '#BBBBBB')"
          onmouseleave="revertBackgroundColor(this)" onclick="goToSignup()">Sign Up</button>
        <button class="user-entrance" id="login" onmousedown="changeBackgroundColor(this, '#666666')"
          onmouseup="revertBackgroundColor(this)" onmouseenter="changeBackgroundColor(this, '#BBBBBB')"
          onmouseleave="revertBackgroundColor(this)" onclick="goToLogin()">Login</button>
      </div>
    </header>
    <!-- BODY -->
    <div class="content">
      <div class="container">
        <h2 class="title">DISEASE</h2>
        <h3>Hurler syndrome</h3>
        <h3>607014</h3>
        <p>The mucopolysaccharidoses are a group of inherited disorders caused by a lack of specific lysosomal enzymes
          involved in the degradation of glycosaminoglycans (GAGs), or mucopolysaccharides. The accumulation of partially
          degraded GAGs causes interference with cell, tissue, and organ function.
        <br>
        Deficiency of alpha-L-iduronidase can result in a wide range of phenotypic involvement with 3 major recognized
          clinical entities: Hurler (MPS IH), Scheie (MPS IS; 607016), and Hurler-Scheie (MPS IH/S; 607015) syndromes. Hurler
          and Scheie syndromes represent phenotypes at the severe and mild ends of the MPS I clinical spectrum, respectively,
          and the Hurler-Scheie syndrome is intermediate in phenotypic expression (McKusick, 1972).
        </p>  
        <p>MPS I is more frequent than MPS II (Hunter syndrome; 309900), which has no corneal clouding and pursues a
          slower course.
        </p>
        <div class="space"></div>
      </div>
      <div class="container">
        <h2 class="title"> SYMPTOMS </h2>
        <p> The clinical features of Hurler syndrome include coarse facies, corneal clouding, mental retardation, hernias,
          dysostosis multiplex, and hepatosplenomegaly. Children with Hurler syndrome appear normal at birth and develop the
          characteristic appearance over the first years of life 
        </p>
        <div class="space"></div>
      </div>
      <div class="container">
        <h2 class="title"> TREATMENTS </h2>
        <div class="space"></div>
        <h4>Bone Marrow Transplantation (BMT)</h4>
        <p>
          Hugh-Jones (1983) pointed out the importance of early diagnosis of mucopolysaccharidoses because of the effectiveness
          of bone marrow transplantation. He reported that hernia was a feature in 13 of 15 cases of MPS I and in 7 of 9 cases
          of MPS II, and suggested that hernia before the age of 6 months may be a valuable diagnostic clue. 
        </p>
        <div class="space"></div>
        <h4>Enzyme Replacement</h4>
        <p>
          Kakkis et al. (2001) treated 10 patients with MPS I (aged 5 to 22 years) with recombinant human alpha-L-iduronidase
          at a dose of 125,000 U per kg of body weight given intravenously once weekly for 52 weeks. Hepatosplenomegaly 
          decreased significantly in all patients, and the size of the liver was normal for body weight and age in 8 patients
          by 26 weeks. The rate of growth in height and weight increased by a mean of 85%% and 131%, respectively, at 52 weeks
          in the 6 prepubertal patients. The mean maximum range of motion of shoulder flexion and elbow extension increased
          significantly. The number of episodes of apnea and hypopnea during sleep decreased by 61%. New York Heart Association
          functional class improved by 1 or 2 classes in all patients. Urinary glycosaminoglycan excretion decreased after 3
          to 4 weeks of treatment; the mean reduction at 52 weeks was 63% of baseline values. Five patients had transient
          urticaria during infusions. Serum antibodies to alpha-L-iduronidase were detected in 4 patients.
        </p>
        
      </div>
      <div class = "container"> 
        <table  class="rounded-table">
          <thead>
            <tr>
              <th>Gene</th>
              <th>Chromosome</th>
            </tr>
          </thead>
          <tbody>
            <tr class="row">
              <td>IDUA</td>
              <td>4p16.3 </td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
    <!-- FOOTER -->
    <footer>
      <h4>Â© The RareGen GROUP 2024</h4>
    </footer>
    <script src="/js/index.js"></script>
  </body>

</html>